All In MedTech

Device Trial Radar · NCT04886388

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Open-Label, Randomized, Controlled, Parallel-Group Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". Randomized with 668 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

668

Actual

Start

Apr 22, 2021

Primary completion

Mar 9, 2022

Study completion Sep 27, 2022

Sponsor

Lead sponsor
Better TherapeuticsNot on our public-company list
Sponsor type
Industry
First posted
May 14, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) compared to standard medical care in patients with type 2 diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • BT-001Device

    BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.

  • Physician-guided Standard of Care for type 2 diabetesOther

    Current ADA Standard of Care Guidelines for type 2 diabetes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groupsTime frame: Baseline and Day 90

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site

    San Francisco, California

  • Study Site

    Miami, Florida

  • Study Site

    Atlanta, Georgia

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.